A citation-based method for searching scientific literature

Clifford J Bailey, Jorge L Gross, Delphine Hennicken, Nayyar Iqbal, Traci A Mansfield, James F List. BMC Med 2013
Times Cited: 201



Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
Times Cited: 233




List of shared articles



Times cited



Drug Therapy in Obesity: A Review of Current and Emerging Treatments.
David M Williams, Asif Nawaz, Marc Evans. Diabetes Ther 2020
29

Renoprotection with SGLT2 inhibitors in type 2 diabetes over a spectrum of cardiovascular and renal risk.
Francesco Giorgino, Jiten Vora, Peter Fenici, Anna Solini. Cardiovasc Diabetol 2020
9

Evidence-Based Consensus on Positioning of SGLT2i in Type 2 Diabetes Mellitus in Indians.
Awadhesh Kumar Singh, Ambika G Unnikrishnan, Abdul H Zargar, Ajay Kumar, Ashok K Das, Banshi Saboo, Binayak Sinha, Kalyan Kumar Gangopadhyay, Pradeep G Talwalkar, Samit Ghosal,[...]. Diabetes Ther 2019
9

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis.
Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Kris Aubrey-Bassler, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen,[...]. BMJ Open 2019
62

Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities.
Emily Brown, John P H Wilding, Thomas M Barber, Uazman Alam, Daniel J Cuthbertson. Obes Rev 2019
35

SGLT2 Inhibitors: A Review of Their Antidiabetic and Cardioprotective Effects.
Anastasios Tentolouris, Panayotis Vlachakis, Evangelia Tzeravini, Ioanna Eleftheriadou, Nikolaos Tentolouris. Int J Environ Res Public Health 2019
46

Effects of SGLT2 inhibitors on cardiovascular outcomes and mortality in type 2 diabetes: A meta-analysis.
Cai-Yan Zou, Xue-Kui Liu, Yi-Quan Sang, Ben Wang, Jun Liang. Medicine (Baltimore) 2019
24

Short and medium-term efficacy of sodium glucose co-transporter-2 (SGLT-2) inhibitors: A meta-analysis of randomized clinical trials.
Matteo Monami, Francesco Liistro, Alessia Scatena, Besmir Nreu, Edoardo Mannucci. Diabetes Obes Metab 2018
15


Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Dirk Müller-Wieland, Monika Kellerer, Katarzyna Cypryk, Dasa Skripova, Katja Rohwedder, Eva Johnsson, Ricardo Garcia-Sanchez, Raisa Kurlyandskaya, C David Sjöström, Stephan Jacob,[...]. Diabetes Obes Metab 2018
30


Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.
Vasilios Tsimihodimos, Theodosios D Filippatos, Moses S Elisaf. Expert Opin Drug Metab Toxicol 2017
14

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.
Amir Qaseem, Michael J Barry, Linda L Humphrey, Mary Ann Forciea, Nick Fitterman, Carrie Horwitch, Devan Kansagara, Robert M McLean, Timothy J Wilt. Ann Intern Med 2017
106

Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Rhona Johnston, Olalekan Uthman, Ewen Cummins, Christine Clar, Pamela Royle, Jill Colquitt, Bee Kang Tan, Andrew Clegg, Saran Shantikumar, Rachel Court,[...]. Health Technol Assess 2017
27


Hot Topics in Primary Care: Individualizing Dual Therapy for Type 2 Diabetes Mellitus.
Neil S Skolnik, Florence Jaffa, Yan Kiriakov. J Fam Pract 2017
0